Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Intestine Cancer Therapeutics Market, and What Factors Will Drive It?
The market size for therapeutics in intestine cancer has seen robust growth in the past few years. It is projected to expand from its $14 billion worth in 2024 to $15.12 billion in 2025, marking a compound annual growth rate (CAGR) of 8.0%. This growth during the historic period is due to developments in medical research, the rise of cancer cases, the use of chemotherapy and radiation therapies, initiatives towards screening and early detection, along with the discovery of new genetics and biomarkers.
The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $20.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to immunotherapy advancements, precision medicine and personalized therapies, emerging targeted therapies, integration of artificial intelligence (AI), patient-centric approaches. Major trends in the forecast period include liquid biopsy technologies, precision medicine and biomarker research, combination therapies, patient-centric care and supportive therapies, adoption of minimally invasive surgical techniques.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13231&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theIntestine Cancer Therapeutics Market?
The anticipated rise in hereditary colorectal cancer syndromes is predicted to boost the intestine cancer therapeutics market. These syndromes comprise genetic disorders that elevate the possibility of an individual developing colorectal cancer (cancer of the colon or rectum). The role of hereditary colorectal cancer syndromes in intestinal cancer therapeutics is integral, as they offer insights linked to particular genetic mutations that considerably heighten the chances of getting colorectal cancer. For example, as per the Switzerland-based intergovernmental organization, the World Health Organization, by 2040, the occurrences of hereditary colorectal cancer are expected to see a notable upturn, with about 3.2 million new cases and 1.6 million deaths annually. This indicates a 63% increase in new cases and a 73% escalation in deaths in comparison to the current figures. Thus, the surging incidents of hereditary colorectal cancer syndromes are fuelling the expansion of the intestine cancer therapeutics market.
Which Segments in the Intestine Cancer Therapeutics Offer the Most Growth?
The intestine cancer therapeuticsmarket covered in this report is segmented –
1) By Treatment Type: Immunotherapy; Chemotherapy; Other Treatments
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By Application: Hospitals; Homecare; Specialty Centers; Other Applications
Subsegments:
1) By Immunotherapy: Checkpoint Inhibitors; CAR T-Cell Therapy; Cancer Vaccines
2) By Chemotherapy: Adjuvant Chemotherapy; Neoadjuvant Chemotherapy; Palliative Chemotherapy
3) By Other Treatments: Targeted Therapy; Radiation Therapy; Surgery; Hormone Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13231&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theIntestine Cancer Therapeutics Market?# Market?
Asia-Pacific was the largest region in the intestine cancer therapeutics market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the intestine cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Current Market Growth and Trends in the Intestine Cancer Therapeutics Industry?
Prominent businesses in the intestinal cancer therapeutics market are steering towards the creation of novel products such as Lonsurf and are attaining approvals to cater to a larger populace, boost sales and elevate revenue. LONSURF is a fusion of two medicinal substances, trifluridine and tipiracil, used to treat metastatic colorectal cancer in adults. For instance, Taiho Oncology Inc., a pharmaceutical company located in the US, earned approval for Lonsurf from the US Food and Drug Administration in August 2023. Lonsurf is procurable as a solitary oral tablet. Trifluridine functions by halting the expansion of cancer cells, and tipiracil aids trifluridine to function for an extended period by restraining it from disintegration by the body. The sanction of Lonsurf provides individuals with metastatic colorectal cancer and other qualifying cancers, a new treatment alternative that could potentially enhance outcomes and the quality of life.
View the full report here:
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
What Are the Key Elements That Define the Intestine Cancer Therapeutics Market?
Intestine cancer therapeutics refer to the various treatment options available for small intestine and colorectal cancer that affect the digestive system. These treatments aim to remove or manage cancerous cells and improve patient outcomes. The specific treatment plan will depend on the stage of the cancer, the patient’s overall health, and other factors.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13231
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model